Mirador Capital Partners LP Makes New Investment in Astera Labs, Inc. $ALAB

Key Points

• Mirador Capital Partners acquired 11,768 Astera Labs shares worth approximately $5.68 million in the second quarter. Institutional investors and hedge funds collectively own 60.47% of the company.
• Astera Labs reported stronger-than-expected second-quarter results, with revenue rising 104.5% year over year to $392.4 million and EPS of $0.80 versus the $0.69 consensus estimate. Management guided for third-quarter EPS of $1.16–$1.21 and revenue of $540–$560 million.
• Despite strong growth and a “Moderate Buy” analyst consensus, insiders sold 1.24 million shares valued at roughly $358.9 million over the past 90 days. The stock trades at a high valuation, with a P/E ratio of 157.64 and a market capitalization of $54.58 billion.

Mirador Capital Partners LP acquired a new stake in Astera Labs, Inc. (NASDAQ:ALAB - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 11,768 shares of the company's stock, valued at approximately $5,684,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Reflection Asset Management acquired a new position in shares of Astera Labs during the fourth quarter worth $25,000. CX Institutional raised its stake in Astera Labs by 1,330.8% in the second quarter. CX Institutional now owns 186 shares of the company's stock valued at $90,000 after buying an additional 173 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in Astera Labs by 422.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 188 shares of the company's stock valued at $32,000 after buying an additional 152 shares in the last quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA purchased a new stake in Astera Labs during the 4th quarter worth about $33,000. Finally, Wexford Capital LP purchased a new stake in Astera Labs during the 3rd quarter worth about $39,000. 60.47% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Manuel Alba sold 8,491 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $458.38, for a total value of $3,892,104.58. Following the completion of the sale, the director directly owned 286,863 shares of the company's stock, valued at approximately $131,492,261.94. This represents a 2.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Philip Mazzara sold 796 shares of the firm's stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $291.03, for a total transaction of $231,659.88. Following the transaction, the general counsel owned 103,343 shares in the company, valued at approximately $30,075,913.29. This trade represents a 0.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,244,395 shares of company stock valued at $358,865,571 in the last 90 days. Company insiders own 10.40% of the company's stock.

Astera Labs Stock Performance

Shares of ALAB stock opened at $318.43 on Thursday. The stock's 50-day moving average is $360.98 and its two-hundred day moving average is $233.52. Astera Labs, Inc. has a 1 year low of $97.89 and a 1 year high of $499.48. The firm has a market cap of $54.58 billion, a price-to-earnings ratio of 157.64, a PEG ratio of 4.19 and a beta of 3.84.

Astera Labs (NASDAQ:ALAB - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.11. The business had revenue of $392.40 million during the quarter, compared to the consensus estimate of $360.85 million. Astera Labs had a return on equity of 20.46% and a net margin of 30.74%.The business's quarterly revenue was up 104.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.44 EPS. Astera Labs has set its Q3 2026 guidance at 1.160-1.210 EPS. As a group, research analysts predict that Astera Labs, Inc. will post 1.86 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ALAB shares. Northland Securities cut Astera Labs from an "outperform" rating to a "market perform" rating in a research report on Tuesday, May 26th. Rothschild & Co Redburn started coverage on Astera Labs in a research note on Friday, May 1st. They set a "neutral" rating and a $153.00 target price for the company. Stifel Nicolaus upped their price target on Astera Labs from $260.00 to $460.00 and gave the company a "buy" rating in a report on Wednesday, June 24th. JPMorgan Chase & Co. increased their price target on shares of Astera Labs from $205.00 to $280.00 and gave the company an "overweight" rating in a research note on Wednesday, May 6th. Finally, TD Cowen cut their price objective on shares of Astera Labs from $425.00 to $375.00 and set a "hold" rating on the stock in a report on Wednesday. Thirteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $325.25.

More Astera Labs News

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: Astera Labs reported record Q2 revenue of $392.4 million, up 27% sequentially and 104.5% year over year. Adjusted earnings of $0.80 per share exceeded the $0.69 consensus estimate, while revenue surpassed the $360.85 million estimate. Astera Labs Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management guided for Q3 revenue of $540 million to $560 million and EPS of $1.16 to $1.21, well above consensus estimates of approximately $410.3 million in revenue and $0.73 in EPS. The outlook implies roughly 40% sequential revenue growth. Astera Labs Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Earnings
• Positive Sentiment: Demand for PCIe 6 connectivity products contributed more than half of Q2 sales, while the Scorpio X-Series fabric switch entered volume production one quarter ahead of schedule. The Scorpio ramp is expected to be the primary driver of Q3 growth and supports the company’s AI-infrastructure expansion story. Astera Labs Q2 Earnings Beat on PCIe 6 and Scorpio Strength
• Positive Sentiment: Needham raised its price target to $425 from $260 and maintained a Buy rating, indicating continued analyst confidence in Astera Labs’ growth prospects. Needham Raises Astera Labs Price Target

Astera Labs Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company's product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source